Trials / Completed
CompletedNCT01497652
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Georgetown University · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II \& III at the end of week 14.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline/Placebo | Will receive placebo pills each day for the entire 14 weeks. |
| DRUG | Rasagiline | 0.5 mg for two weeks, then 1 mg for 12 weeks. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2011-12-22
- Last updated
- 2015-12-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01497652. Inclusion in this directory is not an endorsement.